While the “feel good effect” has long been associated with the use of the monoclonal antibody Natalizumab, there is now evidence that the wearing-off of this and other monoclonal antibodies is associated with depression. In fact, more than half of MS patients treated with the monoclonal antibodies Ocrevus, Rituxan, and Natalizumab who were surveyed reported depression as the perceived beneficial effects of these meds were wearing off before the next dose. These patients reported dissatisfaction with their treatment.
Interestingly, the prevalence of these complaints did not vary according to which monoclonal antibody treatment was being used. The other common wearing-off symptoms were fatigue, worsened cognitive function, worsened mobility and increased paresthesias (tingling-like sensations on the skin). The authors of the study concluded that “Depression significantly increases odds of the wearing-off effect, suggesting some psychological component.”
The BeCare MS Link can help you monitor your mood as well as your mobility and other aspects of your neurologic function. By better understanding how your treatments affect you, you can partner with your clinician to optimize your care.
Source:
Harris KA, et al. Wearing off effects with monoclonal antibodies for multiple sclerosis. Presented at: ACTRIMS; Feb. 29-March 2, 2024; West Palm Beach.